Home LiteratureArticle Details
PMID: 19459819 Published · ppublish English Journal Article Research Support, N.I.H., Extramural

Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome.

Weigt SS, Elashoff RM, Huang C, Ardehali A, Gregson AL, Kubak B, Fishbein MC, Saggar R, Keane MP, Saggar R, Lynch JP, Zisman DA, Ross DJ, Belperio JA

Abstract

Multiple infections have been linked with the development of bronchiolitis obliterans syndrome (BOS) post-lung transplantation. Lung allograft airway colonization by Aspergillus species is common among lung transplant recipients. We hypothesized that Aspergillus colonization may promote the development of BOS and may decrease survival post-lung transplantation. We reviewed all lung transplant recipients transplanted in our center between January 2000 and June 2006. Bronchoscopy was performed according to a surveillance protocol and when clinically indicated. Aspergillus colonization was defined as a positive culture from bronchoalveolar lavage or two sputum cultures positive for the same Aspergillus species, in the absence of invasive pulmonary Aspergillosis. We found that Aspergillus colonization was strongly associated with BOS and BOS related mortality in Cox regression analyses. Aspergillus colonization typically preceded the development of BOS by a median of 261 days (95% CI 87-520). Furthermore, in a multivariate Cox regression model, Aspergillus colonization was a distinct risk factor for BOS, independent of acute rejection. These data suggest a potential causative role for Aspergillus colonization in the development of BOS post-lung transplantation and raise the possibility that strategies aimed to prevent Aspergillus colonization may help delay or reduce the incidence of BOS.

MeSH Terms
Adolescent Adult Aged Antifungal Agents/therapeutic use Aspergillosis/complications,prevention & control Aspergillus/pathogenicity Bronchiolitis Obliterans/epidemiology Female Humans Incidence Kaplan-Meier Estimate Lung/microbiology Lung Transplantation/adverse effects,immunology Male Middle Aged Proportional Hazards Models Retrospective Studies Risk Factors Transplantation, Homologous Young Adult
Chemicals
Antifungal Agents
Authors & Affiliations
14 authors, click to expand affiliations / ORCID
Weigt S S
Division of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. sweigt@mednet.ucla.edu
Elashoff R M
Huang C
Ardehali A
Gregson A L
Kubak B
Fishbein M C
Saggar R
Keane M P
Saggar R
Lynch J P
Zisman D A
Ross D J
Belperio J A
References (40)
40 references, click to expand
  1. Putative virulence factors of Aspergillus fumigatus.
    Clin Exp Allergy. 2000 Apr;30(4):476-84 PMID: 10718844
  2. Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome.
    Transplantation. 2008 Mar 15;85(5):771-4 PMID: 18337673
  3. Protease-dependent activation of epithelial cells by fungal allergens leads to morphologic changes and cytokine production.
    J Allergy Clin Immunol. 2000 Jun;105(6 Pt 1):1185-93 PMID: 10856154
  4. Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors.
    J Heart Lung Transplant. 1998 Dec;17(12):1255-63 PMID: 9883768
  5. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management.
    J Heart Lung Transplant. 2003 Mar;22(3):258-66 PMID: 12633692
  6. [Surveillance of invasive mold infections in lung transplant recipients: effect of antimycotic prophylaxis with itraconazole and voriconazole].
    Mycoses. 2005;48 Suppl 1:51-5 PMID: 15826288
  7. Aspergillus infections in lung transplant recipients: risk factors and outcome.
    Clin Microbiol Infect. 2005 May;11(5):359-65 PMID: 15819861
  8. Spectrum of Aspergillus infection in lung transplant recipients: case series and review of the literature.
    Chest. 2001 Jan;119(1):169-75 PMID: 11157600
  9. Aspergillus airway colonization and invasive disease after lung transplantation.
    Chest. 1997 Nov 5;112(5):1160-4 PMID: 9367451
  10. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation.
    J Heart Lung Transplant. 1993 Sep-Oct;12(5):713-6 PMID: 8241207
  11. Proteases from Aspergillus fumigatus induce release of proinflammatory cytokines and cell detachment in airway epithelial cell lines.
    J Infect Dis. 1997 Jul;176(1):300-3 PMID: 9207388
  12. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.
    Clin Infect Dis. 2008 Jun 15;46(12):1813-21 PMID: 18462102
  13. Aspergillus infection in lung transplant recipients with cystic fibrosis: risk factors and outcomes comparison to other types of transplant recipients.
    Chest. 2003 Mar;123(3):800-8 PMID: 12628881
  14. Obstructive bronchial aspergillosis after heart transplantation.
    Mycoses. 1993 Nov-Dec;36(11-12):425-8 PMID: 7935576
  15. Aspergillus infection in lung transplant patients: incidence and prognosis.
    Eur J Clin Microbiol Infect Dis. 2007 Dec;26(12):879-86 PMID: 17874329
  16. Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation.
    Transplantation. 1991 Feb;51(2):433-8 PMID: 1847251
  17. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report-2007.
    J Heart Lung Transplant. 2007 Aug;26(8):782-95 PMID: 17692782
  18. Stanford experience with obliterative bronchiolitis after lung and heart-lung transplantation.
    Ann Thorac Surg. 1996 Nov;62(5):1467-72; discussion 1472-3 PMID: 8893585
  19. Aspergillus infection in single and double lung transplant recipients.
    Transplantation. 1996 Mar 27;61(6):915-9 PMID: 8623160
  20. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland.
    Am J Med. 1997 Aug;103(2):106-13 PMID: 9274893
  21. Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation.
    J Thorac Cardiovasc Surg. 1997 Aug;114(2):195-202 PMID: 9270635
  22. Outcome of lung transplantation in patients with mycetomas.
    Chest. 2002 Jan;121(1):128-34 PMID: 11796441
  23. Risk factors for the development of obliterative bronchiolitis after lung transplantation.
    J Heart Lung Transplant. 1996 Dec;15(12):1200-8 PMID: 8981205
  24. Proteases from Aspergillus fumigatus induce interleukin (IL)-6 and IL-8 production in airway epithelial cell lines by transcriptional mechanisms.
    J Infect Dis. 1999 Oct;180(4):1267-74 PMID: 10479157
  25. Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients.
    Clin Infect Dis. 1998 Mar;26(3):753-5 PMID: 9524855
  26. Human herpesvirus 6 in bronchalveolar lavage fluid after lung transplantation: a risk factor for bronchiolitis obliterans syndrome?
    Am J Transplant. 2005 Dec;5(12):2982-91 PMID: 16303014
  27. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria.
    J Heart Lung Transplant. 2002 Mar;21(3):297-310 PMID: 11897517
  28. Chlamydia pneumoniae serology in donors and recipients and the risk of bronchiolitis obliterans syndrome after lung transplantation.
    Transplantation. 2005 Feb 15;79(3):269-75 PMID: 15699755
  29. Investigation and control of aspergillosis and other filamentous fungal infections in solid organ transplant recipients.
    Transpl Infect Dis. 2000 Mar;2(1):22-8 PMID: 11429006
  30. Bronchiolitis obliterans in recipients of single, double, and heart-lung transplantation.
    Chest. 1995 Apr;107(4):973-80 PMID: 7705164
  31. Chlamydia pneumoniae infection after lung transplantation.
    J Heart Lung Transplant. 2005 Feb;24(2):131-6 PMID: 15701426
  32. Long-term survival after lung transplantation depends on development and severity of bronchiolitis obliterans syndrome.
    J Heart Lung Transplant. 2007 Jul;26(7):681-6 PMID: 17613397
  33. Effect of development of antibodies to HLA and cytomegalovirus mismatch on lung transplantation survival and development of bronchiolitis obliterans syndrome.
    J Thorac Cardiovasc Surg. 1998 Nov;116(5):812-20 PMID: 9806388
  34. Nebulized amphotericin B prophylaxis for Aspergillus infection in lung transplantation: study of risk factors.
    J Heart Lung Transplant. 2001 Dec;20(12):1274-81 PMID: 11744410
  35. Altered levels of CC chemokines during pulmonary CMV predict BOS and mortality post-lung transplantation.
    Am J Transplant. 2008 Jul;8(7):1512-22 PMID: 18513272
  36. Age and immune response in organ transplantation.
    Transplantation. 2005 Jan 27;79(2):127-32 PMID: 15665758
  37. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death.
    Am J Respir Crit Care Med. 2004 Jul 15;170(2):181-7 PMID: 15130908
  38. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant.
    Am J Transplant. 2005 Aug;5(8):2031-6 PMID: 15996256
  39. Analysis of risk factors for the development of bronchiolitis obliterans syndrome.
    Am J Respir Crit Care Med. 1999 Mar;159(3):829-33 PMID: 10051258
  40. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group.
    J Heart Lung Transplant. 1996 Jan;15(1 Pt 1):1-15 PMID: 8820078
Article Info
Journal
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
Abbr.
Am J Transplant
ISSN
1600-6143
Published
2009-08-00
Epub
2009-00-13
Pages
1903-11
Language
English
Region
United States
NLM ID
100968638
PMCID
PMC4214373
Subset
IM
Grants
NHLBI NIH HHS · HL080206 · United States
NHLBI NIH HHS · L30 HL097951 · United States
NHLBI NIH HHS · HL060606 · United States
NHLBI NIH HHS · K23 HL094746 · United States
NHLBI NIH HHS · R01 HL080206-04 · United States
NHLBI NIH HHS · K23HL094746 · United States
NHLBI NIH HHS · U01 HL060606 · United States
NHLBI NIH HHS · R01 HL080206 · United States
Corrections
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com